titlesubtitle

roundpokertable| Puli Pharmaceutical's stock claim: Xinpai violations will be ordered to correct, and damaged shareholders can claim compensation

editor|
16

Log in to Sina Finance APP to search [Xinpi] to view more evaluation levels

Recently, he has represented many major impact casesroundpokertableZhang Xiangbing, a lawyer from Jiangsu Boaixing Law Firm, specifically reminded that Puli Pharmaceuticals (Rights Protection) was ordered to correct its violations of the letter, and damaged shareholders could claim compensation. (Zhang Xiangbing's lawyer's column)

On April 16, 2024, Hainan Puli Pharmaceutical Co., Ltd.(hereinafter referred to as Puli Pharmaceutical) issued a notice on receiving the decision of the Hainan Securities Regulatory Bureau to order the company to correct administrative supervision measures, saying: "Our bureau found that during the on-site inspection, the disclosure of financial information such as operating income and profits in the company's 2021 and 2022 annual reports was inaccurate, and our bureau decided to take administrative supervision measures against your company to order corrections."

roundpokertable| Puli Pharmaceutical's stock claim: Xinpai violations will be ordered to correct, and damaged shareholders can claim compensation

Lawyer Zhang Xiangbing believes that the judicial interpretation of the Supreme People's Court stipulates that if the information disclosure obligor violates laws, administrative regulations, rules and normative documents formulated by regulatory authorities on information disclosure, which constitutes a false statement, the damaged investor can sue for compensation in accordance with the law. The actual losses incurred include: loss of investment balance, commissions and stamp duty on the loss of investment balance.

Due to illegal information disclosure, Puli Pharmaceutical was ordered to make corrections by the Hainan Securities Regulatory Bureau. According to judicial interpretation, shareholders can claim compensation for damage.

Currently, Lawyer Zhang Xiangbing is representing Puli Pharmaceuticals in the litigation of damaged investors. The claim conditions are:

Impaired investors who bought Puli Pharmaceuticals shares between April 26, 2022 and April 16, 2024 and still held the shares at the close of trading on April 16, 2024 can sue for losses. (Puli Pharmaceutical Rights Protection Entrance)

Investors who meet the conditions for claim can contact the lawyer team of Zhang Xiangbing of Jiangsu Boaixing Law Firm and provide the following documents: a copy of their ID card, a securities account inquiry confirmation form stamped with the seal of the securities company's business department, and the original stock transaction statement (the stock was purchased for the first time since the first time), detailed contact information.

Lawyer Zhang Xiangbing stated:

The final claim conditions shall be subject to the court's determination.

(Lawyer Zhang Xiangbing, a securities rights lawyer, graduated from Southwest University of Political Science and Law with a master's degree in law, and is currently a lawyer at Jiangsu Boaixing Law Firm. He is good at representing securities litigation and financial rights protection cases. He has many years of experience in investor rights protection litigation. He has successfully represented or is representing hundreds of investor rights protection cases, and has represented many cases with major social impact and landmark significance. The investor v. Solin Shares (Rights Protection) and Dong Jiangao cases were selected as one of the top ten typical cases of securities misrepresentation liability disputes by Shenzhen Intermediate People's Court; the Bank of China's "Crude Oil Treasure" civil case was selected as one of the top ten commercial cases in national courts in 2020)